Waters Corporation (ETR:WAZ)
Germany · Delayed Price · Currency is EUR | Market Cap | 34.56B +128.2% |
| Revenue (ttm) | 4.06B +52.5% |
| Net Income | 145.67M -74.8% |
| EPS | 1.94 -80.0% |
| Shares Out | n/a |
| PE Ratio | 237.28 |
| Forward PE | 26.18 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2 |
| Open | 343.20 |
| Previous Close | 359.80 |
| Day's Range | 343.20 - 350.00 |
| 52-Week Range | 299.00 - 362.80 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About Waters
Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. The company operates through two segments, Waters and TA. The company designs, manufactures, sells, and services liquid chromatography, as well as mass spectrometry (MS) technology systems and supports products, including chromatography columns, and other consumable products. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, p... [Read more]
Financial Performance
In 2025, Waters's revenue was $3.17 billion, an increase of 6.99% compared to the previous year's $2.96 billion. Earnings were $642.63 million, an increase of 0.75%.
Financial numbers in USD Financial StatementsNews
Waters Earnings Call Transcript: Q2 2026
Q2 results exceeded guidance with strong growth across all divisions, especially in pharma, academic/government, and acquired BD businesses. Full-year guidance was raised, with robust margin expansion and cost savings expected. New product launches and strategic partnerships further strengthen growth prospects.
Waters Earnings release: Q2 2026
Waters released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Waters Slides: Q2 2026
Waters has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Waters Quarterly report: Q2 2026
Waters has published its Q2 2026 quarterly earnings report on August 4, 2026.
Waters Corporation (NYSE: WAT) Reports Second Quarter 2026 Financial Results
Second Quarter 2026 Highlights Total reported revenue of $1.645 billion surpassed the high end of the guidance range, driven by broad-based outperformance across both organic revenue and the acquired ...
Waters Launches Industry's Most Sensitive and Robust Clinical IVD System with Xevo TQ Absolute XR IVD Mass Spectrometer
Brings Xevo™ TQ Absolute XR Mass Spectrometer's industry-leading tandem quadrupole MS sensitivity to clinical applications across women's health, cancer assessment, and toxicology. Offers 5x greater s...
Waters Corporation Schedules Second Quarter 2026 Earnings Conference Call
MILFORD, Mass., July 2, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) will hold its Q2 2026 financial results conference call on Tuesday, August 4, 2026, at 8:00 a.m.
IMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precision Medicine
LONDON--(BUSINESS WIRE)--IMU Biosciences, a biotechnology company decoding the immune system to pioneer a paradigm shift in how we understand, diagnose, and treat disease, and Waters Corporation (NYSE...
Waters Launches Coin Cell Differential Scanning Calorimeter (DSC) to Advance Battery Safety with Integrated Thermal, Evolved Gas, and Electrochemical Analysis
Integrates heat flow, evolved gas, and electrochemical analysis in a single experiment, enabling earlier insights into thermal runaway. Unique whole-cell design eliminates cell teardown, reducing samp...
Waters Launches Industry-First Reversed-Phase Bioseparation Columns to Deliver Up to 3x Faster GLP-1 Characterization and 2x Faster LNP Component Analysis
Faster run times for GLP-1, insulin, and LNP drug substance testing accelerates biopharmaceutical development timelines and reduces production bottlenecks. Delivers up to 2x increase in resolving powe...
Waters Transcript: Jefferies Global Healthcare Conference 2026
Double-digit growth was driven by new products, recurring revenue, and strong pharma performance, especially in China and India. Integration efforts are yielding commercial and operational synergies, with accelerated product launches and localization supporting future gains. Pricing improvements and innovation in mass spectrometry and antibodies are set to drive continued growth.
Waters Announces FDA 510(k) Clearance of BD BACTEC FXI Culture System, Enabling Broader Access to Bloodstream Infection Diagnostics
FDA 510(k)-cleared BD BACTEC™ FXI Culture System now available to U.S. market, enabling broader access to confident bloodstream infection diagnostics. Achieves a 3-hour faster time to detection (~15% ...
Waters Introduces Unrivaled Sensitivity and Speed to Benchtop HRMS with Xevo MRT P10 MS, Accelerating Multiomics Research
Delivers up to 20x improvement in MS/MS sensitivity and 2x faster acquisition speeds, enabling deeper biological insight for next-generation multiomics, therapeutic, and high-throughput workflows. Ide...
Waters Unveils Cyclic IMS P20 MS: The New Benchmark in Structural and Spatial Omics
>10x step-change in MS/MS sensitivity paired with multipass Cyclic™ Ion Mobility Spectrometry (IMS) reveals subtle biological differences for earlier, previously unattainable detection of disease sign...
Waters Corporation to Present at the Jefferies Global Healthcare Conference
MILFORD, Mass., May 18, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D.
Waters CEO highlights China as key innovation source in the biopharma market
Waters CEO Udit Batra highlighted China as a global biopharmaceutical powerhouse. He said that innovation has fueled a rapid expansion of contract manufacturers moving into full drug development.
Waters raises annual profit forecast as biosciences unit drives growth
Lab equipment maker Waters raised its annual profit forecast on Tuesday after beating quarterly estimates, driven by robust demand for drug development tools and the strong performance of its biosci...
Waters Earnings Call Transcript: Q1 2026
Strong Q1 performance with double-digit organic growth, robust execution in acquired businesses, and 20% adjusted EPS growth led to raised 2026 revenue and EPS guidance. Integration and synergy realization are ahead of plan, with new product launches and China localization supporting future growth.
Waters Slides: Q1 2026
Waters has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
Waters Earnings release: Q1 2026
Waters released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Waters Quarterly report: Q1 2026
Waters has published its Q1 2026 quarterly earnings report on May 5, 2026.
Waters Corporation (NYSE: WAT) Reports First Quarter 2026 Financial Results
First Quarter 2026 Highlights Total reported revenue of $1.267 billion exceeded the high end of the guidance range by $56 million, driven by strong outperformance in both organic revenue and the acqui...
Waters Corporation Schedules First Quarter 2026 Earnings Conference Call
MILFORD, Mass., April 20, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q1 2026 financial results conference call on Tuesday, May 5, 2026 at 8:30 a.m.
Waters Debuts Industry-First Extended-Range MALS Detector for UHPLC/UPLC, Powering Rapid Characterization of Large Molecules
Delivers up to 4x faster chromatographic run times to accelerate decisions across discovery, development, and quality workflows.1,3 Achieves 10x improvement in absolute molar mass and extended sizing,...
Waters Proxy statement: Proxy filing
Waters filed a proxy statement on April 9, 2026, providing details for shareholder voting and corporate governance matters.